Organon Acquired by Sun Pharmaceutical Industries | Healthcare M&A Deal

Sun Pharmaceutical Industries has acquired Organon, a pharmacy business in the United States, for $11.75 billion. Sun Pharmaceutical Industries acquisitions expand Organon’s global women’s health and general medicines portfolio, including biosimilars, across major markets in the US, Europe, China, Canada, and Brazil. The Sun Pharmaceutical Industries acquisitions also add Organon’s manufacturing footprint in six facilities across the EU and emerging markets, supporting a strategic acquisition into biosimilars and branded generics. The merger acquisition is a strategic acquisition by a public pharma buyer, signed as an all-cash deal with an enterprise valuation of $11.75 billion and expected to close in early 2027, subject to regulatory and shareholder approvals.